School of Nursing, University of São Paulo (EEUSP), São Paulo, Brazil.
Clinics Hospital of Faculty of Medicine, University of São Paulo - HCFMUSP, São Paulo, Brazil.
JBI Evid Synth. 2021 Sep;19(9):2382-2388. doi: 10.11124/JBIES-20-00353.
This review will synthesize the best available evidence on the effectiveness of leukocyte reduction by comparing post-storage and pre-storage filters. The review will consider the following clinical outcomes: transfusion reactions, bacterial infection, length of stay, and mortality.
Transfusion is a relevant therapy, but it is not risk-free. Leukocyte reduction can be performed either by apheresis or by pre- or post-storage filters in order to reduce the risk of transfusion reactions, transmission of some diseases, alloimmunization, and platelet refractoriness. It can also reduce the length of hospital stay and the use of antibiotics.
Studies comparing the transfusion of leukocyte reduction through post-storage filters with pre-storage filters in patients of any age who received a transfusion and the clinical outcomes resulting from the transfusion will be considered for inclusion. Studies in Portuguese, English, and Spanish will be considered, with no publication time limit.
The research sources will include MEDLINE (PubMed), CINAHL (EBSCO), PsycINFO, Scopus, The Cochrane Library, Web of Science Core Collection, Embase, LILACS, and gray literature sources. The selection of titles and abstracts will be carried out by two independent reviewers, and the critical evaluation of the studies will be based on JBI tools. The data of interest for the review question will be extracted using JBI SUMARI. A narrative synthesis will be performed as will a meta-analysis and risk assessment of publication bias, if possible.
PROSPERO: CRD42020192202.
本综述将通过比较储存前后过滤器,综合关于白细胞减少效果的最佳现有证据。综述将考虑以下临床结果:输血反应、细菌感染、住院时间和死亡率。
输血是一种有效的治疗方法,但并非没有风险。白细胞减少可以通过单采或储存前或后过滤器来实现,以降低输血反应、某些疾病传播、同种免疫和血小板反应性降低的风险。它还可以减少住院时间和抗生素的使用。
将纳入比较储存前后过滤器白细胞减少输血与储存前过滤器白细胞减少输血的患者(任何年龄)的研究,以及输血后产生的临床结果。纳入研究语言为葡萄牙语、英语和西班牙语,无发表时间限制。
研究来源将包括 MEDLINE(PubMed)、CINAHL(EBSCO)、PsycINFO、Scopus、The Cochrane Library、Web of Science 核心合集、Embase、LILACS 和灰色文献来源。两名独立评审员将对标题和摘要进行筛选,研究的批判性评估将基于 JBI 工具。使用 JBI SUMARI 提取感兴趣的数据。如果可能,将进行叙述性综合以及发表偏倚的荟萃分析和风险评估。
PROSPERO:CRD42020192202。